Children formula food for regulating immunity as well as preparation method and application of children formula food

Abstract

The invention provides a children formula food capable of regulating immunity as well as a preparation method and application of the children formula food. The invention firstly provides the infant formula food, the infant formula food is infant formula food or children formula food, the infant formula food comprises zinc, lactoferrin and yeast beta-glucan, and the raw materials of the infant formula food comprise bovine colostrum, lactoferrin and yeast beta-glucan. The mass ratio of the zinc to the lactoferrin to the bovine colostrum to the yeast beta-glucan is (2-10): (20-670): (140: 400): (10-60) according to the dry matter mass of the zinc element, the lactoferrin, the bovine colostrum and the yeast beta-glucan. The children formula food can regulate immunity, and especially prevent and / or improve immunosuppression caused by zinc deficiency or insufficient zinc intake.

Description

Technical Field

[0001] The invention belongs to the technical field of children's formula food, and specifically relates to a children's formula food containing DHA, ARA and phospholipids and being helpful for regulating immunity and application thereof. Background Art

[0002] Immunity is the umbrella of human health. With the improvement of living standards, consumers' demand for health is increasing. The role of dietary nutrition on immunity is gradually gaining more and more attention from consumers, and the importance of immunity is becoming increasingly prominent. The immune system is the body's natural defense mechanism, playing a huge role in fighting diseases and infections, regulating inflammation, etc. Children are usually more susceptible to microbial infections and more serious diseases than adults due to their immature immune systems. It is reported that respiratory infections often occur in children under 5 years old. Therefore, improving children's immunity and enhancing their resistance to infectious diseases will help their healthy growth.

[0003] The body's nutritional status is closely related to the immune function and they influence each other. Malnutrition leads to impaired immune function, making it easy to get infected or even get a tumor, while severe infection or long-term chronic infection can induce or aggravate malnutrition. Reasonable nutrition is the basic condition for maintaining the body's normal immune function. Nutrients are the material basis for the normal operation of the human immune system and play an important role in both nonspecific and specific immunity. At present, research on nutrition and immunity mainly focuses on proteins, lipids, vitamin A, vitamin E, vitamin C, vitamin D, iron, zinc, selenium, etc., especially micronutrients, which play a key role in the immune system.

[0004] Zinc is the second most abundant trace element in the human body. It is essential for protein metabolism and contraction, nucleic acid metabolism, and the stability of cell membranes. Zinc participates in the activity of enzymes as a cofactor of more than 300 coenzymes and is necessary for a variety of cellular metabolic functions. Therefore, zinc has important physiological functions in growth and development, immune system development and function. The zinc deficiency rate in children is relatively high, and there is a problem of low bioavailability. Zinc deficiency in the human body will cause systemic symptoms, manifested as short stature, genital dysplasia, iron deficiency anemia, hepatosplenomegaly, and lack of energy. Animal experimental studies have shown that animal models with zinc deficiency during growth have atrophy of immune organs, decreased lymphocytes, and decreased immune function.

[0005] According to literature search, there are a variety of compositions that can be added to products to achieve the effect of regulating immunity, and the compositions mainly include but are not limited to one or more of lactoferrin, trace elements, yeast B-glucan, syringic acid (N-acetylneuraminic acid), Bifidobacterium lactis, complex vitamins, complex minerals, etc. However, there are few reports on providing effective solutions for low immunity caused by zinc deficiency.

[0006] Therefore, there is a need to provide solutions for zinc deficiency, especially in the field of healthy diet for children, and to prevent and / or improve the immunity reduction caused by zinc deficiency. Summary of the invention

[0007] An object of the present invention is to provide a pediatric formula food capable of regulating immunity.

[0008] Another object of the present invention is to provide related applications of the pediatric formula food.

[0009] On the one hand, the present invention provides a pediatric formula food, which is an infant formula food or a children's formula food, and the pediatric formula food includes zinc, lactoferrin and yeast β-glucan, and the raw materials of the pediatric formula food include bovine colostrum, and the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2-10): (20-670): (140:400): (10-60) based on the dry weight of zinc element and lactoferrin, bovine colostrum and yeast β-glucan.

[0010] Lactoferrin is a glycoprotein belonging to the transferrin family. It has multiple functions such as promoting iron absorption in the body, anti-vitamin activity, anti-virus, immune regulation, promoting neurodevelopment and cognition, and osteogenic activity. Bovine colostrum refers to the milk secreted by dairy cows in the first few days after natural delivery. It is rich in lactoferrin, immunoglobulin, lysozyme, lactoperoxidase, antimicrobial peptides and growth factors and other active ingredients. It has multiple biological activities such as regulating immunity, improving gastrointestinal health, promoting bone health and accelerating wound healing. Yeast β-glucan is a polysaccharide widely found in yeast, fungi, bacteria, seaweed, barley and oats. It is a nutritional functional raw material with the effects of lowering cholesterol, lowering blood sugar, immunomodulation, anti-oxidation and anti-inflammatory.

[0011] The present invention has found that combining bovine colostrum, lactoferrin and yeast β-glucan in a specific ratio has a synergistic effect on improving immunosuppression caused by zinc deficiency or insufficient zinc intake. Even in the case of lower zinc intake, symptoms such as immunosuppression caused by zinc deficiency or insufficient zinc intake can be prevented and / or improved.

[0012] In the present invention, unless otherwise specified, the pediatric includes infants, toddlers or children. The infant refers to infants aged 0-12 months (including infants aged 0-6 months and older infants aged 6-12 months), the toddler refers to children aged 1-3 years old, and the child refers to children aged 3 to 18 years old (under 19 years old), especially younger children aged 3 to 6 years old (under 7 years old).

[0013] According to a specific embodiment of the present invention, the pediatric formula food of the present invention is an infant formula food (infant formula food, toddler formula food) or a children's formula food (such as children's modulated milk powder). Wherein, the total protein content of the infant formula food converted into dry matter is 7.8g-22.8g / 100g, the proportion of whey protein in the total protein is 40%-75%, the fat content is 14.9g-33.8g / 100g, and the carbohydrate content is 40.7g-79.3g / 100g. Wherein, the total protein content of the children's formula food converted into dry matter is 16.5g-30g / 100g, the fat content is 10g-35g / 100g; the carbohydrate content is 40g-70g / 100g.

[0014] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (24-670): (143-400): (12-60).

[0015] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (50-670): (145-400): (21.4-60);

[0016] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (80-670): (155-400): (23-50).

[0017] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of lactoferrin, bovine colostrum and yeast β-glucan is (5-20): (40-80): (6-12). The amount of zinc can be determined with reference to the above-mentioned ratio range of zinc to lactoferrin.

[0018] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of lactoferrin, bovine colostrum and yeast β-glucan is (40-60): (40-80): (6-12). The amount of zinc can be determined with reference to the above-mentioned ratio range of zinc to lactoferrin.

[0019] According to some specific embodiments of the present invention, in the pediatric formula food of the present invention, the mass ratio of lactoferrin, bovine colostrum and yeast β-glucan is (80-120): (40-80): (6-12). The amount of zinc can be determined with reference to the above-mentioned ratio range of zinc to lactoferrin.

[0020] According to a specific embodiment of the present invention, in the infant formula food of the present invention, each component raw material can be commercially available.

[0021] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw materials providing zinc include one or more of zinc sulfate, zinc gluconate, zinc glycinate, zinc oxide, zinc lactate, zinc citrate, zinc chloride, zinc acetate, zinc carbonate, and zinc citrate (trihydrate).

[0022] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the bovine colostrum can be liquid bovine colostrum or bovine colostrum powder. Unless otherwise specified, the mass ratio or weight of bovine colostrum to lactoferrin described in the present invention is based on the amount of dry matter. In some specific embodiments of the present invention, the bovine colostrum is a powdered or finely crystalline product made from bovine colostrum as a raw material through sterilization, centrifugal defatting, low-temperature drying and other processes, wherein the protein content is ≥40%, and the immunoglobulin (IgG) content is ≥10%.

[0023] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the lactoferrin may be a lactoferrin raw material from cow's milk, goat's milk and their products. For example, the raw material for providing lactoferrin may be pure lactoferrin powder, or may include but not limited to whole milk powder, skim milk powder, casein and whey protein powder. In some specific embodiments, whey protein powder is preferably used as the raw material for providing lactoferrin. Unless otherwise specified, the ratio of the lactoferrin to other functional components in the pediatric formula food of the present invention is based on the content of lactoferrin in the raw material.

[0024] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the yeast β-glucan is produced by extraction, acid-base treatment, spray drying and other steps using saccharomyces cerevisiae as raw material, wherein the content of β-glucan is ≥70%, which meets the requirements of the announcement on approving 5 items such as Camellia chrysantha and Inula japonica (small black medicine) as new resource foods (No. 9, 2010). Unless otherwise specified, the ratio of the yeast β-glucan to other functional components in the pediatric formula food of the present invention is based on the content of β-glucan in the raw materials.

[0025] According to a specific embodiment of the present invention, the pediatric formula food of the present invention contains 2.6-16.7 mg / 100 g of zinc, 26-1111 mg / 100 g of food dry matter, 150-670 mg / 100 g of food dry matter, and 23-100 mg / 100 g of food dry matter, respectively.

[0026] According to a specific embodiment of the present invention, the pediatric formula food of the present invention contains 2.6-16.7 mg / 100 g of zinc, 30-1000 mg / 100 g of food dry matter, 158-670 mg / 100 g of food dry matter, and 23.8-100 mg / 100 g of food dry matter, respectively.

[0027] According to a specific embodiment of the present invention, the pediatric formula food of the present invention contains 2.6-16.7 mg / 100 g of zinc, 50-1000 mg / 100 g of food dry matter, 160-650 mg / 100 g of food dry matter, and 23-50 mg / 100 g of food dry matter, respectively.

[0028] According to a specific embodiment of the present invention, the pediatric formula food of the present invention, the infant formula food, in terms of dry matter, has a linoleic acid content of 2700-6000 mg / 100 g and an α-linolenic acid content of 270-600 mg / 100 g.

[0029] According to a specific embodiment of the present invention, the pediatric formula food of the present invention is a formula food for infants of 0-6 months, a formula food for older infants of 6-12 months, or a formula food for toddlers of 12-36 months.

[0030] According to a specific embodiment of the present invention, the formula food for infants aged 0-6 months of the present invention has a total protein content of 8.5-16 g / 100 g in terms of dry matter, whey protein accounts for 60-75% of the total protein, the fat content is 20.5-32.5 g / 100 g, the linoleic acid content is 2700-6000 mg / 100 g, the α-linolenic acid content is 270-600 mg / 100 g, and the carbohydrate content is 50-60 g / 100 g.

[0031] According to a specific embodiment of the present invention, the formula food for older infants aged 6-12 months of the present invention has a total protein content of 10-20 g / 100 g, a whey protein content of 40-75% of the total protein, a fat content of 20-30 g / 100 g, a linoleic acid content of 2700-4500 mg / 100 g, an α-linolenic acid content of 270-450 mg / 100 g, and a carbohydrate content of 50-60 g / 100 g.

[0032] According to a specific embodiment of the present invention, the formula food for infants aged 12-36 months of the present invention has a total protein content of 10-20 g / 100 g, a fat content of 20-30 g / 100 g, a linoleic acid content of 2700-4500 mg / 100 g, an α-linolenic acid content of 270-450 mg / 100 g, and a carbohydrate content of 50-60 g / 100 g in terms of dry matter.

[0033] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw materials providing total protein include: raw milk (cow / sheep), whole milk powder (cow / sheep), skimmed milk powder (cow / sheep), whey protein powder (cow / sheep), desalted whey powder (cow / sheep), β-casein, etc. One or more.

[0034] According to a specific embodiment of the present invention, in the pediatric formula food of the present invention, the raw materials providing fat may include vegetable oil or OPO structured fat in addition to the basic raw materials containing milk fat.

[0035] According to a specific embodiment of the present invention, a part of the carbohydrates in the pediatric formula food of the present invention can come from basic raw materials containing lactose such as milk, whole milk powder and / or skimmed milk powder, etc., and lactose raw materials can also be additionally added to provide carbohydrates.

[0036] According to a specific embodiment of the present invention, in the children's formula food of the present invention, in addition to the above-mentioned components, the conventional components of infant formula or children's modulated milk powder may also be included, for example, nutrients, dietary fiber, inositol, L-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, one or more of nucleotides may also be included. Preferably, a composite nutrient package is included. In some preferred embodiments, the children's formula food includes 0-20 portions of nutrients, and the nutrients include vitamins and minerals, or further selectively includes dietary fiber (fructooligosaccharides, galacto-oligosaccharides, polyfructose, breast milk oligosaccharides, etc.), inositol, L-carnitine, docosahexaenoic acid, eicosatetraenoic acid, lutein, nucleotides, one or more of animal bifidobacterium lactis subspecies. The compound nutrients mainly include: compound vitamins: vitamin A, vitamin D, vitamin E, vitamin K1, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, folic acid, pantothenic acid, vitamin C, biotin; compound minerals: sodium, potassium, calcium, phosphorus, copper, iron, zinc, manganese, iodine, selenium, magnesium, potassium and their derivatives. The sources, contents and usage of the vitamins and minerals mentioned above should comply with the national standards and relevant regulations for infant formula and modified milk powder.

[0037] In addition, the pediatric formula of the present invention may be in the form of a solid composition or a liquid composition.

[0038] In a specific embodiment, the pediatric formula food of the present invention is a dairy product, which can be a solid dairy product or a liquid dairy product. Specifically, it can be in the form of cheese, liquid dairy product, milk flakes or milk powder.

[0039] It is understandable that for different types of pediatric formula foods, the content of each functional substance in the final product should be appropriately adjusted within the range permitted by relevant standards and specifications.

[0040] On the other hand, the present invention also provides a method for preparing the pediatric formula food, the method comprising:

[0041] The zinc, lactoferrin, bovine colostrum and yeast beta-glucan composition are mixed with other raw materials in the formula by adopting a wet method, a dry method or a dry-wet composite production process. The mixed material is homogenized after filtering and removing impurities, and is further used to prepare the pediatric formula food.

[0042] According to a specific embodiment of the present invention, the present invention provides a method for preparing infant formula or children's modulated milk powder, the method comprising:

[0043] ①Ingredient selection and preparation:

[0044] Infant formula food, wherein, based on the preparation of 1000 parts by weight of the powdered infant formula food, the raw material composition of the powdered infant formula food includes: 0-7000 parts by weight of raw cow milk, 0-600 parts by weight of desalted whey powder, 0-500 parts by weight of lactose, 0-500 parts by weight of skim milk powder, 0-400 parts by weight of edible vegetable blending oil, 0-100 parts by weight of prebiotics, 0-120 parts by weight of whey protein powder, 0-20 parts by weight of phospholipids, 0-20 parts by weight of vitamins, 0-40 parts by weight of casein, and 0-30 parts by weight of minerals;

[0045] Based on the preparation of 1000 parts by weight of the infant formula liquid milk, the raw material composition of the infant formula liquid milk includes: 0-7000 parts by weight of raw cow's milk, 0-500 parts by weight of skim milk powder, 0-500 parts by weight of desalted whey powder, 0-500 parts by weight of lactose, 0-400 parts by weight of edible vegetable blending oil, 0-100 parts by weight of prebiotics, 0-120 parts by weight of whey protein powder, 0-10 parts by weight of phospholipids, 0-40 parts by weight of casein, 0-20 parts by weight of vitamins, and 0-30 parts by weight of minerals.

[0046] Based on the preparation of 1000 parts by weight of the powdered children's formula milk powder, the raw material composition of the powdered children's formula milk powder includes: 0-7000 parts by weight of raw cow's milk, 0-500 parts by weight of skim milk powder, 0-600 parts by weight of desalted whey powder, 0-120 parts by weight of whey protein powder, 0-500 parts by weight of lactose, 0-50 parts by weight of prebiotics, 0-5 parts by weight of choline, 0-10 parts by weight of phospholipids, 0-20 parts by weight of vitamins, and 0-30 parts by weight of minerals;

[0047] Raw cow's milk (partially skimmed): provides basic milk protein and fat source.

[0048] Whey and / or whey concentrate (liquid or powder): provides high quality whey protein.

[0049] Edible vegetable blended oil (may contain 1,3-dioleyl-2-palmityl triglyceride): provides essential fatty acids.

[0050] Lactose: serves as the main carbohydrate source.

[0051] Skim milk powder: as a base protein and lactose source.

[0052] Minerals, trace elements, vitamins: provide necessary nutrients to maintain the comprehensive nutritional needs of children.

[0053] The minerals are one or a combination of two or more of complex minerals, milk mineral salts and calcium carbonate.

[0054] Prebiotics (such as galacto-oligosaccharides, fructo-oligosaccharides, isomerized lactose, fucoidan, etc.): provide support for intestinal health.

[0055] ②Control of mass ratio of ingredients:

[0056] Infant formula or children's formula milk powder contains zinc, lactoferrin, bovine colostrum and yeast β-glucan composition. The amount added to the food is calculated based on the amount of zinc in the composition, which can be 2.6-17 mg / 100g of food dry matter. Among them, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2-10): (20-670): (140: 400): (10-60). In some embodiments, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (24-670): (143-400): (12-60). In some embodiments, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (50-670): (145-400): (21.4-60). In some embodiments, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (80-670): (155-400): (23-50). In some embodiments, the mass ratio of lactoferrin, bovine colostrum and yeast β-glucan is (5-20): (40-80): (6-12). In some embodiments, the mass ratio of lactoferrin, bovine colostrum and yeast β-glucan is (40-60): (40-60): (40-80): (6-12). In some embodiments, the mass ratio of lactoferrin, bovine colostrum and yeast β-glucan is (80-120): (40-80): (6-12). The amount of zinc can be determined with reference to the aforementioned ratio range of zinc to lactoferrin.

[0057] ③Mixing and preparation:

[0058] Mix the above ingredients in appropriate proportions to ensure uniform distribution and formulation stability.

[0059] ④Production and processing:

[0060] The infant formula food or children's formula milk powder food is prepared by using a wet method or a dry method or a dry-wet composite production process to mix zinc, lactoferrin, bovine colostrum and yeast β-glucan composition with other raw materials in the formula. The mixed material is homogenized after filtering and removing impurities, and the homogenization temperature is not less than 50° C. and the pressure is not less than 120 bar;

[0061] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 40% to 60%;

[0062] The concentrated material is sterilized at above 80°C for 10 to 60 seconds;

[0063] The sterilized material is dried by a spray drying tower (inlet air temperature 150°C to 200°C, exhaust air temperature 80°C to 120°C, negative pressure -10 to -2 mmWG, high pressure pump pressure 140 to 250 bar), then introduced into a fluidized bed for secondary drying, and finally dry mixed to obtain the infant formula food or children's formula milk powder.

[0064] In the preparation method of the present invention, ① preparation and mass ratio control of ingredients: the specific ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan composition optimizes the formula, can regulate immunity, and ensure that children can fully absorb and utilize these key nutrients. ② Mixing and formulation: ensure that the ingredients are evenly mixed in proportion to ensure the consistency and stability of the formula, so that the nutritional components of each batch of products are balanced and meet the expected nutritional standards. ③ Production and processing: use advanced production processes such as homogenization, pasteurization, spray drying or UHT sterilization to ensure the safety and quality of the product, extend the shelf life, and retain the activity and stability of the nutrients.

[0065] On the other hand, the present invention also provides the use of the pediatric formula food in preparing a product for regulating immunity. The product can be the pediatric formula food of any of the aforementioned schemes of the present invention, or can be other products further prepared based on the pediatric formula food of the present invention.

[0066] According to some specific embodiments of the present invention, regulating immunity comprises:

[0067] Preventing and / or improving the reduction of immune organ index caused by zinc deficiency or insufficient zinc intake; preferably, the immune organ index includes thymus index and / or spleen index;

[0068] Prevent and / or improve the decrease in NK cell activity caused by zinc deficiency or insufficient zinc intake;

[0069] Prevent and / or improve the decreased proliferation capacity of spleen lymphocytes caused by zinc deficiency or insufficient zinc intake;

[0070] Prevent and / or improve growth retardation caused by zinc deficiency or inadequate zinc intake; and / or

[0071] Increase the content of sIgA in the colon mucosa.

[0072] According to a specific embodiment of the present invention, when the food is used, the amount of yeast β-glucan used is 10 to 50 mg / day, preferably less than 50 mg / day, based on the yeast β-glucan therein.

[0073] According to a specific embodiment of the present invention, when the food is used, the amount of yeast β-glucan used in the composition is 11.5-49 mg / day, calculated as the yeast β-glucan therein.

[0074] According to a specific embodiment of the present invention, when the food is used, the amount of yeast β-glucan used in the composition is 12.5-49 mg / day, calculated as the yeast β-glucan therein.

[0075] In general, the present invention mixes lactoferrin, bovine colostrum and yeast β-glucan in a certain proportion, or further compounds them with zinc to prepare pediatric formula food, which helps to regulate immunity. The specific effects are reflected in alleviating the decline of thymus index and spleen index, increasing NK cell activity and spleen lymphocyte proliferation ability, and increasing the sIgA content in the colon mucosa, thereby improving the body and intestinal immunity in multiple dimensions. BRIEF DESCRIPTION OF THE DRAWINGS

[0076] Figure 1 The effects of different groups of test substances in specific embodiments of the present invention on NK cell activity are shown.

[0077] Figure 2 The results show the effects of different groups of test substances on the proliferation capacity of spleen lymphocytes in the specific examples of the present invention.

[0078] Figure 3 The effects of different groups of test substances in specific embodiments of the present invention on colon mucosal sIgA are shown. DETAILED DESCRIPTION

[0079] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing the specific embodiments rather than for limiting the scope of protection of the present invention.

[0080] When numerical ranges are given in the embodiments, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected unless otherwise specified in the present invention.

[0081] Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0082] In addition to the specific methods, equipment, and materials used in the embodiments, based on the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art that are similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.

[0083] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the technical field.

[0084] In the animal experiment, lactoferrin was commercially available lactoferrin powder, wherein the lactoferrin content was 95%. Bovine colostrum was commercially available bovine colostrum powder, wherein the protein content was 63.2%, and the immunoglobulin (IgG) content was ≥10%. The source of yeast β-glucan was commercially available yeast β-glucan powder, wherein the β-glucan content was ≥70%.

[0085] Animal experiment on the efficacy of nutritional composition in regulating immunity

[0086] 1. Experimental animals and groups

[0087] Newly weaned (21 days) SPF SD male rats were housed in an animal room with an ambient temperature of 20-23°C, a relative humidity of 40%-70%, a 12-h artificial lighting / dark cycle, and a ventilation rate of ≥15 times / h.

[0088] The rat diet was prepared with reference to the current common experimental animal pure diet formula AIN-93G. Among them, casein was soaked in 1% disodium EDTA aqueous solution for many times to remove zinc, then rinsed with deionized ultrapure water and dried to prepare a zinc-deficient diet. A certain amount of zinc sulfate was added to the zinc-deficient diet to prepare diets with different zinc contents (5mg / kg, 10mg / kg, 30mg / kg), and the feed zinc concentration was detected by atomic absorption spectrophotometer standard method.

[0089] After 4 days of adaptive feeding, 56 SD rats were randomly divided into 7 groups according to body weight, with 8 rats in each group. Lactoferrin, bovine colostrum and yeast β-glucan were administered by gavage. The experimental groups are shown in Table 1. The animals were weighed regularly and the intervention lasted for 5 weeks. After the experiment, the rats were killed by cervical dislocation and quickly dissected. The femur and other tissues were removed and properly preserved for subsequent experiments.

[0090] Table 1 Experimental groups

[0091]

[0092] Note: (1) Experimental Example 1 is the normal zinc control group; Experimental Example 2 is the zinc deficiency group, which is 1 / 6 of the normal zinc control group;

[0093] (2) The dosage per kilogram of body weight of rats is calculated based on their weight, food intake, and zinc content in the feed. A zinc content of 10 mg / kg in the feed translates to a dosage of 1-1.5 mg / kg per kilogram of body weight of rats.

[0094] Based on the average weight range of 15-42kg for children aged 3-12 years old, the daily supplement of zinc is 2-10mg, the daily supplement of lactoferrin is 20-670mg, the daily supplement of bovine colostrum is 140-400mg, and the daily supplement of yeast β-glucan is 10-60mg.

[0095] (II) Experimental methods

[0096] 1. Organ index

[0097] The thymus and spleen of the rat were removed, and the residual blood was absorbed with filter paper and weighed (mg), respectively divided by the weight of the mouse (g), and then multiplied by 10 to obtain the thymus index and spleen index. Thymus index = (thymus weight / rat weight) × 100%; spleen index = (spleen weight / rat weight) × 100%.

[0098] 2. Proliferative response of spleen lymphocytes

[0099] The proliferation reaction of spleen lymphocytes was determined by MTT method. The spleen was sterilely removed, and the spleen cell suspension was prepared in RPMI-1640 medium to form a cell suspension of 2.5×105 / mL. 0.2mL of the cell suspension was added to a 96-well plate, and 3 replicate wells were added. 20μL of PHA was added to each well to make the final concentration of 10μg / mL. After incubation at 37°C and 5% CO2 for 68h, MTT (5mg / mL) diluted in PBS was added to each well, and the culture was continued for 4h. Then 100μL of 10% DMSO was added, and the plate was allowed to stand for 20min after sufficient shaking. The OD value was measured with an enzyme marker at a wavelength of 570nm.

[0100] 3. NK cell activity detection

[0101] Take about 0.5g of spleen in a sterile beaker, cut it into pieces with ophthalmic scissors, crush it with the inner core of a syringe, filter it with 4 layers of sterile gauze, take the filtrate and gently cover it on the upper layer of 1.5mL lymphocyte separation solution, centrifuge it at 2000r / min for 10min, aspirate the suspended lymphocyte layer, transfer it to a 1.5mL centrifuge tube, add a small amount of D-Hanks buffer, centrifuge it at 1600r / min for 2min, discard the supernatant, add 0.8mL D-Hanks to each tube, suspend it, centrifuge it; repeat once, discard the supernatant, and resuspend it with 0.5mL cell culture medium 1640 (containing 10% calf serum and penicillin and streptomycin 100U / mL). Take the separated lymphocyte suspension and place it in a 24-well plate, add cell culture medium to 0.5mL, culture it in a 37℃ 5% CO2 incubator for 4h, remove the adherent cells, and then take the cell suspension and count it.

[0102] MTT method was used for detection. 80 μL of the above cell solution was added to a 96-well plate as effector cells. Then, MDCC-MSB1 tumor cells in the logarithmic growth phase were taken as target cells and added to the effector cell wells; effector cell wells and target cell wells were set up at the same time, with 3 replicates in each well. Incubate in a 37℃5% CO2 incubator for 6-8 hours, add 15 μL of MTT solution with a mass concentration of 5g / L to each well, continue to culture for 4 hours, add 80 μL of lysis solution, lyse at 37℃5% CO2 for 2 hours, and read the OD value at a wavelength of 570nm on an enzyme reader. Calculate the killing percentage and compare the differences between the groups.

[0103] 4. Determination of sIgA content in colonic mucosa

[0104] The colon tissue was spread on filter paper, cut longitudinally to expose the mucosal surface, and the intestinal mucus was gently scraped 5 times with a glass slide and collected in an EP tube. Then 1 mL of 0.01 mol·L-1 phosphate buffer (PBS) containing 0.1% protease inhibitor was added, mixed thoroughly, centrifuged at 3000 r·min-1 for 15 min, and the supernatant was taken and frozen at -80°C for testing. Thawed at room temperature before testing, and the sIgA content in the colon mucosa was detected by ELISA according to the instructions of the kit.

[0105] (III) Experimental results

[0106] 1. Effects of different experimental cases on the growth and development of spleen and thymus

[0107] Immune organs are the basis of the body's immunity. The thymus is the body's most important central immune organ, where immune cells occur, differentiate and mature; while the spleen is an important peripheral immune organ, where mature T cells and B cells reside. The level of the thymus index and spleen index can indirectly reflect the body's overall immune level to a certain extent, and is of great significance in the evaluation of immune function.

[0108] Compared with Experimental Example 1 (normal control group), the spleen index and thymus index of Experimental Example 2 decreased significantly, indicating that 5 weeks of zinc-deficient feed feeding damaged the immunity of rats during the growth period, causing atrophy of spleen and thymus tissue, and successfully constructed a model suitable for children with low immunity; compared with Experimental Example 2, the spleen index and thymus index of Experimental Examples 3, 4 and 5 increased significantly, indicating that simply increasing the zinc content in the feed, increasing lactoferrin + bovine colostrum + yeast β-glucan, and increasing zinc and lactoferrin at the same time improved the atrophy of immune organs, and alleviated the reduction of immune organ index caused by zinc deficiency or insufficient zinc intake to a certain extent. Compared with Experimental Example 2, the spleen index and thymus index of Experimental Examples 6, 7 and 8 increased significantly, the effect was significantly better than Experimental Example 4, and gradually approached Experimental Example 1, and there was no significant difference between the normal control group (Table 2). The above experimental results indicate that the nutritional composition of zinc + lactoferrin + bovine colostrum + yeast β-glucan can effectively alleviate the decrease in immune organ index caused by zinc deficiency or insufficient zinc intake, and the effect is better than that of the zinc-fortified group. The components synergistically alleviate the decrease in immune organ index, showing a dose-dependent relationship.

[0109] Table 2 Effects of different experimental cases on the growth and development of spleen and thymus

[0110] Group Spleen index (%) Thymus index (%) Experimental Example 1 0.281±0.008a 0.247±0.009a Experimental Example 2 0.189±0.004g 0.197±0.007d Experimental Example 3 0.224±0.006e 0.233±0.006ab Experimental Example 4 0.206±0.003f 0.212±0.006c Experimental Example 5 0.216±0.004e 0.232±0.003ab Experimental Example 6 0.229±0.003de 0.229±0.002ab Experimental Example 7 0.241±0.004cd 0.238±0.007ab Experimental Example 8 0.261±0.005b 0.244±0.006a

[0111] 2. Effects of different experimental cases on NK cell activity

[0112] NK cells are functional cells of natural defense that can perform immune clearance and immune surveillance on the body. Their killing range is much greater than that of T cells. They can exert immune functions in the absence of allergen stimulation, kill most infected cells, and protect the body from infection.

[0113] The results show that Figure 1), compared with Experimental Example 1 (normal control group), the NK cell activity of Experimental Example 2 decreased significantly, indicating that after 5 consecutive weeks of feeding zinc-deficient feed, the immune cell activity of rats was suppressed, resulting in reduced immunity. Compared with Experimental Example 2, the NK cell activity of Experimental Example 4 increased, but the difference was not significant; compared with Experimental Example 2, the NK cell activity of rats in Experimental Examples 3 and Experimental Examples 5-8 increased significantly, and the effect gradually increased; compared with Experimental Examples 4 and 5, Experimental Examples 7 and Experimental Examples 8 can significantly improve NK cell activity. Compared with Experimental Example 3, the NK cell activity of Experimental Example 7 increased significantly. The above results indicate that at the experimental dose, simply increasing the zinc content in the feed has no significant improvement on the NK cell activity of rats; the nutritional compositions of zinc + lactoferrin, lactoferrin + bovine colostrum + yeast β-glucan and zinc + lactoferrin + bovine colostrum + yeast β-glucan can alleviate the decreased NK cell activity of rats caused by zinc deficiency to a certain extent, but the nutritional composition of zinc + lactoferrin + bovine colostrum + yeast β-glucan has the best intervention effect, and the effect is better than that of the zinc-fortified group, zinc + lactoferrin group and lactoferrin + bovine colostrum + yeast β-glucan group. The components synergistically alleviate the decreased NK cell activity.

[0114] 3. Effects of different experimental cases on the proliferation of spleen lymphocytes

[0115] Lymphocytes are an important component of the immune system, and their number often affects the strength of the body's immunity. This experiment measured the proliferation of spleen lymphocytes in each group.

[0116] The results show that Figure 2 ), compared with Experimental Example 1 (normal control group), the spleen lymphocyte proliferation rate of Experimental Example 2 decreased significantly, indicating that after 5 consecutive weeks of feeding zinc-deficient feed, the proliferation of rat immune cells was inhibited and the immunity was reduced. Compared with Experimental Example 2, the proliferation capacity of rat spleen lymphocytes in Experimental Examples 3 and 4 increased, but the difference was not significant; compared with Experimental Example 2, the proliferation capacity of rat spleen lymphocytes in Experimental Examples 5-8 increased significantly, and the effect gradually increased. Compared with Experimental Example 3, the proliferation capacity of rat spleen lymphocytes in Experimental Example 7 increased significantly. The above results indicate that at the experimental dose, only increasing the zinc content in the feed and only increasing lactoferrin + bovine colostrum + yeast β-glucan have no significant improvement on the proliferation ability of rat splenic lymphocytes; the nutritional compositions of zinc + lactoferrin and zinc + lactoferrin + bovine colostrum + yeast β-glucan can alleviate the decreased proliferation ability of rat splenic lymphocytes caused by zinc deficiency to a certain extent; the nutritional composition of zinc + lactoferrin + bovine colostrum + yeast β-glucan has the best intervention effect, and the effect is better than that of the zinc-fortified group, zinc + lactoferrin group and lactoferrin + bovine colostrum + yeast β-glucan, and the components synergistically alleviate the decreased proliferation ability of splenic lymphocytes.

[0117] 4. Effects of different experimental cases on colonic mucosal sIgA

[0118] sIgA is a functional indicator of intestinal mucosal immunity and the main antibody for local anti-infection of the intestinal mucosa. When the intestinal mucosa is damaged, it will produce sIgA to resist the invasion of pathogens.

[0119] The results of sIgA in colon mucosa showed ( Figure 3 ), compared with Experimental Example 1 (normal control group), the sIgA in the colon mucosa of Experimental Example 2 decreased significantly, indicating that immunity decreased after 5 consecutive weeks of feeding zinc-deficient feed. Compared with Experimental Example 2, the sIgA content in the colon mucosa of Experimental Example 4 increased, but the difference was not significant; compared with Experimental Example 2, the sIgA in the colon mucosa of Experimental Examples 3 and Experimental Examples 5-8 increased significantly, and the effect gradually increased. Compared with Experimental Example 3, the sIgA content in the colon mucosa of Experimental Example 7 increased significantly; compared with Experimental Examples 4 and Experimental Examples 5, the sIgA content in the colon mucosa of Experimental Examples 6-8 increased significantly, and there was no significant difference compared with Experimental Example 1 (normal control group). The above results suggest that at the experimental dose, only increasing the zinc content in the feed has no significant increase in the sIgA content in the colonic mucosa of rats; the nutritional compositions of lactoferrin + bovine colostrum + yeast β-glucan, zinc + lactoferrin and zinc + lactoferrin + bovine colostrum + yeast β-glucan can increase the sIgA content in the colonic mucosa to varying degrees, but the intervention effect of the nutritional composition of zinc + lactoferrin + bovine colostrum + yeast β-glucan is the best, and the effect is better than that of the zinc-fortified group, zinc + lactoferrin group and lactoferrin + bovine colostrum + yeast β-glucan group. The components synergistically increase the sIgA content in the colonic mucosa, thereby enhancing intestinal immunity.

[0120] Example 1

[0121] The present embodiment provides a powdered children's formula milk powder, in which the total protein content of the powdered children's formula milk powder is 20.5g / 100g, the fat content is 13.5g / 100g; the carbohydrate content is 58g / 100g, the zinc content is 10mg / 100g, the bovine colostrum powder content is 220mg / 100g, the yeast β-glucan content is 50mg / 100g, and the lactoferrin content is 85mg / 100g.

[0122] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0123] 3400 parts of raw milk, 325 parts of skimmed milk powder, 215 parts of lactose, 15 parts of galacto-oligosaccharides, 14.9 parts of calcium carbonate, 6 parts of isomerized lactose, 4 parts of milk mineral salts, 2.5 parts of complex vitamins, 2 parts of phospholipids, 1 part of complex minerals, and 1.1 parts of choline.

[0124] The powdered children's formula milk powder of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0125] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0126] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0127] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0128] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0129] The concentrated material was sterilized at 85°C for 15 seconds;

[0130] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0131] Upon testing, it was found that various indicators of the finished product met the food standard requirements for children's formula milk powder.

[0132] Example 2

[0133] The present embodiment provides a powdered children's formula milk powder, in which the total protein content of the powdered children's formula milk powder is 20g / 100g, the fat content is 18g / 100g; the carbohydrate content is 54g / 100g, the zinc content is 5mg / 100g, the bovine colostrum powder content is 150mg / 100g, the yeast β-glucan content is 15mg / 100g, and the lactoferrin content is 85mg / 100g.

[0134] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0135] 4400 parts of raw milk, 210 parts of skimmed milk powder, 200 parts of lactose, 15 parts of galacto-oligosaccharides, 14.9 parts of calcium carbonate, 7 parts of milk mineral salts, 6 parts of isomerized lactose, 2.5 parts of complex vitamins, 2 parts of phospholipids, 1 part of complex minerals, and 1.1 parts of choline.

[0136] The powdered children's formula milk powder of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0137] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0138] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0139] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0140] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0141] The concentrated material was sterilized at 85°C for 15 seconds;

[0142] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0143] Upon testing, it was found that various indicators of the finished product met the food standard requirements for children's formula milk powder.

[0144] Example 3

[0145] The present embodiment provides a powdered children's formula milk powder, in which the total protein content of the powdered children's formula milk powder is 20g / 100g, the fat content is 17g / 100g; the carbohydrate content is 52g / 100g; the zinc content is 9mg / 100g, the bovine colostrum powder content is 200mg / 100g, the yeast β-glucan content is 60mg / 100g, and the lactoferrin content is 60mg / 100g.

[0146] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0147] 4400 parts of raw milk, 200 parts of skimmed milk powder, 160 parts of lactose, 90 parts of galacto-oligosaccharides, 14.9 parts of calcium carbonate, 5 parts of milk mineral salts, 2.5 parts of complex vitamins, 2 parts of phospholipids, 1 part of complex minerals, and 1.1 parts of choline.

[0148] The powdered children's formula milk powder of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0149] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0150] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0151] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0152] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0153] The concentrated material was sterilized at 85°C for 15 seconds;

[0154] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0155] After testing, all indicators of the finished product meet the requirements of relevant food standards.

[0156] Example 4

[0157] The present embodiment provides a powdered infant formula food, wherein the total protein content of the powdered infant formula food is 10.5 g / 100 g, the fat content is 28.3 g / 100 g, the carbohydrate content is 53.7 g / 100 g, the zinc content is 7 mg / 100 g, the bovine colostrum powder content is 180 mg / 100 g, the yeast β-glucan content is 20 mg / 100 g, the lactoferrin content is 70 mg / 100 g; and the proportion of whey protein in the total protein is 66%.

[0158] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0159] 1000 parts of raw milk, 375 parts of desalted whey powder, 230 parts of edible vegetable blending oil, 150 parts of lactose, 45 parts of galacto-oligosaccharides, 27 parts of whey protein powder, 22 parts of casein, 20 parts of fructo-oligosaccharides, 4 parts of phospholipids, 3.5 parts of complex vitamins, and 13 parts of minerals.

[0160] The powdered infant formula food of this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0161] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0162] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0163] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0164] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0165] The concentrated material was sterilized at 85°C for 15 seconds;

[0166] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0167] After testing, all indicators of the finished product meet the standard requirements for infant formula food.

[0168] Example 5

[0169] The present embodiment provides a powdered follow-on infant formula food, wherein the total protein content of the powdered follow-on infant formula food is 12g / 100g, the fat content is 23g / 100g, the carbohydrate content is 57.5g / 100g, the zinc content is 6mg / 100g, the bovine colostrum powder content is 300mg / 100g, the yeast β-glucan content is 25mg / 100g, the lactoferrin content is 50mg / 100g; and the proportion of whey protein in the total protein is 48%.

[0170] This embodiment is achieved by compounding the following raw materials in parts by weight, and its raw material composition includes (preparing 1000 parts by weight):

[0171] 1000 parts of raw milk, 275 parts of desalted whey powder, 230 parts of lactose, 183 parts of edible vegetable blending oil, 135 parts of skimmed milk powder, 14 parts of galacto-oligosaccharide, 10 parts of whey protein powder, 10 parts of casein, 7 parts of oligofructose, 4 parts of phospholipids, 3.5 parts of complex vitamins, and 13 parts of minerals.

[0172] The powdered formula food for older infants in this embodiment is prepared by a dry-wet composite production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, concentration and sterilization, spray drying, and dry mixing to obtain a finished product; the specific steps include:

[0173] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0174] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0175] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0176] Subsequently, the homogenized material is concentrated, and the dry matter weight content of the concentrate is 50%;

[0177] The concentrated material was sterilized at 85°C for 15 seconds;

[0178] The sterilized material is dried by a spray drying tower (inlet air temperature 175°C, exhaust air temperature 100°C, negative pressure -8mmWG, high pressure pump pressure 200bar), and then introduced into a fluidized bed for secondary drying to obtain a powder.

[0179] After testing, all indicators of the finished product meet the requirements of relevant food standards.

[0180] Example 6

[0181] The present embodiment provides a liquid infant formula food, wherein the total protein content of the liquid infant formula food is 13.8 g / 100 g, the fat content is 22 g / 100 g, the carbohydrate content is 55.6 g / 100 g, the zinc content is 8 mg / 100 g, the bovine colostrum powder content is 270 mg / 100 g, the yeast β-glucan content is 23 mg / 100 g, and the lactoferrin content is 80 mg / 100 g.

[0182] This embodiment is achieved by compounding the following raw materials in parts by weight, and the raw material composition includes:

[0183] 1000 parts of raw milk, 250 parts of skimmed milk powder, 225 parts of desalted whey powder, 190 parts of lactose, 170 parts of edible vegetable blending oil, 17 parts of galacto-oligosaccharides, 8 parts of fructo-oligosaccharides, 4 parts of whey protein powder, 4 parts of phospholipids, 1 part of casein, 3.5 parts of complex vitamins, and 11 parts of minerals.

[0184] The liquid infant formula food of this embodiment is prepared by the existing production process, and the preparation method is as follows: pasteurization of raw milk, batching, mixing, preheating, homogenization, high temperature instant sterilization, aseptic filling and sealing to obtain the finished product; the specific steps include:

[0185] The raw milk is inspected, roughly filtered, stored after cooling, and placed in a mixing tank after pasteurization (85°C, 15s);

[0186] Mix the ingredients such as large and small ingredients in proportion to ensure uniform distribution and formula stability;

[0187] The mixed material is homogenized after filtering and removing impurities, with a homogenization temperature of 50°C and a pressure of 120 bar;

[0188] Subsequently, the homogenized material is sterilized at 135°C for 5 seconds and then aseptically filled.

[0189] After testing, all indicators of the finished product meet the requirements of relevant food standards.

[0190] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.

Claims

1. A pediatric formula food, the pediatric formula food being an infant formula food or a children's formula food, the pediatric formula food comprising zinc, lactoferrin and yeast β-glucan, and the raw materials of the pediatric formula food comprising bovine colostrum, and the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan, based on the dry weight of zinc element and lactoferrin, bovine colostrum and yeast β-glucan, is (2-10): (20-670): (140:400): (10-60); in, The infant formula food has a total protein content of 7.8g-22.8g / 100g, whey protein accounts for 40%-75% of the total protein, the fat content is 14.9g-33.8g / 100g, and the carbohydrate content is 40.7g-79.3g / 100g; the children's formula food has a total protein content of 16.5g-30g / 100g, the fat content is 10g-35g / 100g, and the carbohydrate content is 40g-70g / 100g.

2. The pediatric formula food according to claim 1, wherein: The mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (24-670): (143-400): (12-60); Preferably, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10): (50-670): (145-400): (21.4-60); Preferably, the mass ratio of zinc, lactoferrin, bovine colostrum and yeast β-glucan is (2.4-10):(80-670):(155-400):(23-50).

3. The pediatric formula food according to claim 1 or 2, wherein: The raw materials providing zinc include one or more of zinc sulfate, zinc gluconate, zinc glycinate, zinc oxide, zinc lactate, zinc citrate, zinc chloride, zinc acetate, zinc carbonate, and zinc citrate (trihydrate).

4. The pediatric formula food according to any one of claims 1 to 3, wherein: The food contains zinc, lactoferrin, bovine colostrum and yeast β-glucan at 2.6-16.7 mg / 100 g food dry matter, 26-1111 mg / 100 g food dry matter, 150-670 mg / 100 g food dry matter and 23-100 mg / 100 g food dry matter respectively; Further preferably, the food contains 2.6-16.7 mg / 100 g of food dry matter, 30-1000 mg / 100 g of food dry matter, 158-670 mg / 100 g of food dry matter, and 23.8-100 mg / 100 g of food dry matter of zinc, lactoferrin, bovine colostrum, and yeast β-glucan, respectively; Further preferably, the food contains 2.6-16.7 mg / 100 g of zinc, 50-1000 mg / 100 g of food dry matter, 160-650 mg / 100 g of food dry matter, and 23-50 mg / 100 g of food dry matter, respectively.

5. The pediatric formula food according to any one of claims 1 to 4, wherein: The infant formula food has a linoleic acid content of 2700-6000 mg / 100 g and an α-linolenic acid content of 270-600 mg / 100 g in terms of dry matter.

6. The pediatric formula food according to claim 1, which is a formula food for infants aged 0-6 months, a formula food for older infants aged 6-12 months, or a formula food for infants aged 12-36 months; wherein: Formula foods for infants aged 0-6 months have a total protein content of 8.5-16 g / 100 g, whey protein accounting for 60-75% of the total protein, fat content of 20.5-32.5 g / 100 g, linoleic acid content of 2700-6000 mg / 100 g, α-linolenic acid content of 270-600 mg / 100 g, and carbohydrate content of 50-60 g / 100 g. Formula foods for older infants aged 6-12 months have a total protein content of 10-20 g / 100 g, whey protein accounting for 40-75% of the total protein, fat content of 20-30 g / 100 g, linoleic acid content of 2700-4500 mg / 100 g, α-linolenic acid content of 270-450 mg / 100 g, and carbohydrate content of 50-60 g / 100 g. The total protein content of formula food for infants aged 12-36 months is 10-20g / 100g, the fat content is 20-30g / 100g, the linoleic acid content is 2700-4500mg / 100g, the α-linolenic acid content is 270-450mg / 100g, and the carbohydrate content is 50-60g / 100g.

7. A method for preparing the pediatric formula food according to any one of claims 1 to 6, the method comprising: The zinc, lactoferrin, bovine colostrum and yeast beta-glucan composition are mixed with other raw materials in the formula by adopting a wet method, a dry method or a dry-wet composite production process. The mixed material is homogenized after filtering and removing impurities, and is further used to prepare the pediatric formula food.

8. Use of the pediatric formula food according to any one of claims 1 to 7 in the preparation of a product for regulating immunity.

9. The use according to claim 8, wherein: The immune regulation includes: Preventing and / or improving the reduction of immune organ index caused by zinc deficiency or insufficient zinc intake; preferably, the immune organ index includes thymus index and / or spleen index; Prevent and / or improve the decrease in NK cell activity caused by zinc deficiency or insufficient zinc intake; Prevent and / or improve the decreased proliferation capacity of spleen lymphocytes caused by zinc deficiency or insufficient zinc intake; Prevent and / or improve growth retardation caused by zinc deficiency or inadequate zinc intake; and / or Increase the content of sIgA in the colon mucosa.

10. The use according to claim 8 or 9, wherein: Calculated on the basis of yeast β-glucan in pediatric formula food, the application amount of yeast β-glucan is 10 to 50 mg / day, preferably less than 50 mg / day; Preferably, the amount of yeast β-glucan used in the composition is 11.5 to 49 mg / day; Preferably, the amount of yeast β-glucan used in the composition is 12.5-49 mg / day.

Images